

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**(1) RETIREMENT BY ROTATION OF INDEPENDENT  
NON-EXECUTIVE DIRECTORS**  
**(2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR AND  
INDEPENDENT NON-EXECUTIVE DIRECTORS**

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that (1) Mr. Chen Junfa (“**Mr. Chen**”) and Mr. Wang Zhaohui (“**Mr. Wang**”) will retire by rotation as independent non-executive Directors with effect from the conclusion of the 2023 annual general meeting of the Company to be held on May 22, 2023 (the “**General Meeting**”); and (2) the Board proposes to appoint Mr. Zhang Ping (“**Mr. Zhang**”) as an executive Director, and Mr. Huang Peng (“**Mr. Huang**”) and Mr. Yi Ming (“**Mr. Yi**”) as independent non-executive Directors, subject to approval by the shareholders of the Company (the “**Shareholders**”) at the General Meeting.

**Retirement by Rotation of Independent Non-Executive Directors**

The Board hereby announces that (1) Mr. Chen and Mr. Wang, will retire by rotation as independent non-executive Directors with effect from the conclusion of the General Meeting to be held on May 22, 2023. Mr. Chen and Mr. Wang have confirmed that they do not wish to stand for re-election at the General Meeting after the end of their current term/the fifth session of the Board in order to devote more time to other work arrangements.

Each of Mr. Chen and Mr. Wang has confirmed that he has no disagreement with the Board and that there are no other matters in relation to his resignation that need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board hereby expresses its sincere gratitude to Mr. Chen and Mr. Wang for their valuable contributions to the Company during their tenure of service.

## **Appointment of Executive Director and Independent Non-executive Directors**

The Board proposes to appoint Mr. Zhang as an executive Director, and Mr. Huang and Mr. Yi as independent non-executive Directors, subject to approval by the Shareholders at the General Meeting.

The biographical details of the Directors proposed to be elected at the General Meeting are set out as follows:

### **Executive Director**

#### **(i) Mr. Zhang Ping**

Mr. Zhang Ping (張平), aged 58, is a Chinese national who graduated from Shaanxi Radio and Television University in China in 1992 with a postgraduate degree in English. In 1998, he graduated from Shanxi Jiaotong University in China with a master's degree in Industrial Management.

Mr. Zhang has over 30 years of experience in manufacturing and operations in the pharmaceutical industry. Mr. Zhang served as the General Manager of Hangzhou Innovax Biotech Co., Ltd from November 2021 to April 2022. He served as the Head of Industry Affairs China at Sanofi from January 2002 to November 2021 and was responsible for seven plants across China. He has extensive experience in technical transfer and new product launches. Prior to that, he served as the Head of Manufacturing at Xian Janssen Pharmaceutical Ltd. from February 1988 to February 2002.

The proposed appointment of Mr. Zhang as an executive Director is subject to the approval by the Shareholders at the General Meeting, with effect from the date of the General Meeting and shall end on the expiry of the term of the sixth session of the Board. He can be re-elected upon the expiry of his term according to the articles of association of the Company (“**Articles of Association**”).

After the appointment as an executive Director is approved by the Shareholders at the General Meeting, Mr. Zhang will receive a remuneration comprising basic salary, discretionary bonus and statutory social security benefits from the Company, the amount of which will be determined in accordance with the Articles of Association and relevant regulations after taking into consideration of the assessment of the Group's operating performance for the year.

The Directors confirm that to their best knowledge and belief, having made all reasonable enquires, save as disclosed above, Mr. Zhang does not hold any other position in the Company or any its subsidiaries, nor served as a director of any public company with securities listed on any securities market in Hong Kong or overseas in the past three years and does not have other major appointments and professional qualifications. Mr. Zhang has no relationship with any Director, supervisor, senior management or substantial shareholder or controlling shareholder of the Company, and does not have or is not deemed to have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and has not been subject to any disciplinary action by the China Securities Regulatory Commission or any other relevant authorities or the Stock Exchange.

As at the date of this announcement, save as disclosed above, the Board is not aware of any other matter in connection with Mr. Zhang's appointment that need to be brought to the attention of the Shareholders, nor any information that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities of the Stock Exchange.

### **Independent Non-Executive Directors**

#### **(ii) *Mr. Huang Peng***

Mr. Huang Peng (黃鵬), aged 74, born in 1949, is a Chinese national. He obtained a Ph.D. in Management from Northwestern Polytechnical University in China in 2003. He obtained a master's degree in Economics from Fudan University in China in 1995 and a bachelor's degree in Economic Management from Nanjing University in China in 1985. He is a professor of accounting. Since September 1988, he has been working as an associate professor, professor, department head of accounting, and doctoral supervisor of finance and taxation at Suzhou University in China, and is currently the dean of the Institute of Entrepreneurship for New Era (新時代企業家研究院) at Suzhou University in China. He is also an independent director of the following companies listed on the Shanghai Stock Exchange or the Shenzhen Stock Exchange, namely Jiangsu Asian Star Anchor Chain Co., Ltd. (SHA: 601890), Suzhou Wanxiang Technology Co., Ltd. (SHE: 301180), Jiangsu Jujie Microfiber Technology Group Co., Ltd. (SHE: 300819) and Suzhou Kelida Building & Decoration Co., Ltd. (SHA: 603828). Mr. Huang has obtained a qualification certificate as an independent director recognized by the China Securities Regulatory Commission of the PRC.

The proposed appointment of Mr. Huang as an independent non-executive Director is subject to the approval by the Shareholders at the General Meeting, with effect from the date of the General Meeting and shall end on the expiry of the term of the sixth session of the Board. He can be re-elected upon the expiry of his term according to the Articles of Association.

After Mr. Huang's appointment as an independent non-executive Director is approved by the Shareholders at the General Meeting, Mr. Huang will receive a remuneration comprising basic salary, discretionary bonus and statutory social security benefits from the Company, the amount of which will be determined in accordance with the Articles of Association and relevant regulations after taking into consideration of the assessment of the Group's operating performance for the year. Mr. Huang will receive a director's fee of RMB100,000 per annum. Such remuneration is determined with reference to his experience, roles, responsibilities and market conditions. The above remuneration policy of the independent non-executive Directors is subject to the approval by the Shareholders at the General Meeting.

**(iii) Mr. Yi Ming**

Mr. Yi Ming (易銘), aged 46, born in 1977, is a Chinese national. He obtained a Master's degree in Finance from ISMA Centre, Henley Business School, University of Reading in the United Kingdom in July 2002 and an EMBA master's degree from Guanghai School of Management, Peking University in China in June 2014. He served as Senior Manager of the Investment Banking Department and General Manager of the Investment Department of China Cinda (Hong Kong) Asset Management Company from March 2003 to December 2012. He was the Managing Partner of Zeal (Asia) Asset Management Company from June 2013 to June 2018. He is the Chief Financial Officer of Asia Pacific Aviation Leasing Group Ltd. from October 2018 to the present.

The proposed appointment of Mr. Yi as an independent non-executive Director is subject to the approval by the Shareholders at the General Meeting, with effect from the date of the General Meeting and shall end on the expiry of the term of the sixth session of the Board. He can be re-elected upon the expiry of his term according to the Articles of Association.

After Mr. Yi's appointment as an independent non-executive Director is approved by the Shareholders at the General Meeting, Mr. Yi will receive a remuneration comprising basic salary, discretionary bonus and statutory social security benefits from the Company, the amount of which will be determined in accordance with the Articles of Association and relevant regulations after taking into consideration of the assessment of the Group's operating performance for the year. Mr. Yi will receive a director's fee of RMB100,000 per annum. Such remuneration is determined with reference to his experience, roles, responsibilities and market conditions. The above remuneration policy of the independent non-executive Directors is subject to the approval by the Shareholders at the General Meeting.

The Directors confirm that to their best knowledge and belief, having made all reasonable enquires, save as disclosed above, Mr. Huang and Mr. Yi do not hold any other position in the Company or any its subsidiaries, nor served as a director of any public company with securities listed on any securities market in Hong Kong or overseas in the past three years and do not have other major appointments and professional qualifications. Mr. Huang and Mr. Yi have no relationship with any Director, supervisor, senior management or substantial shareholder or controlling shareholder of the Company, and do not have or are not deemed to have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and have not been subject to any disciplinary action by the China Securities Regulatory Commission or any other relevant authorities or the Stock Exchange.

As at the date of this announcement, save as disclosed above, the Board is not aware of any other matter in connection with Mr. Huang and Mr. Yi's appointment that need to be brought to the attention of the Shareholders, nor any information that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities of the Stock Exchange.

Each of Mr. Huang and Mr. Yi has confirmed that he has meet the independence requirements as set out in Rule 3.13 of the Rules Governing the Listing of Securities of the Stock Exchange.

### **Circular**

A circular containing, among other things, the proposed appointments of Mr. Zhang as an executive Director, and Mr. Huang and Mr. Yi as independent non-executive Directors, along with a notice of the General Meeting, will be despatched to the Shareholders in due course.

Announcement is hereby given.

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, the PRC  
29 March, 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*